INTRODUCTION {#s1}
============

Acute myeloid leukemia (AML) is the second most common pediatric leukemia with poor outcomes indicated by 5-year survival rates of 50-60%\[[@R1], [@R2]\]. Cytarabine is one of the most effective chemotherapeutic agents used in AML treatment and has contributed to improved remission rates and overall survival.\[[@R3]\] Although most patients achieve remission after intensive cytarabine-containing induction therapy, a significant proportion of patients experience relapse. Development of resistance to anti-leukemic agents, such as cytarabine, is one of the biggest challenges in achieving successful treatment outcome in AML. Thus, there is a need to better understand the factors that impact the chemosensitivity of leukemic cells. Previous efforts to identify single nucleotide polymorphisms (SNPs) associated with cytarabine resistance in AML have focused on SNPs within candidate pharmacokinetic genes involved in cytarabine metabolism and transport, as well as a few (LCLs) genome-wide efforts studies using of lymphoblastoid cell lines (LCLs)\[[@R4]--[@R12]\]. One of the limitations of LCLs used in GWAS studies is that these were derived from healthy individuals that are available through the International HapMap project.\[[@R9]--[@R12]\] Given that LCLs do not represent leukemic cells, these cell lines are not the best models to study leukemic cell chemosensitivity to cytarabine. Other efforts have focused on identifying differences in gene expression among AML cell lines with varying sensitivity to cytarabine.\[[@R13]--[@R19]\] To the best of our knowledge, no GWAS has so far been performed to identify SNPs that associate with the sensitivity of AML patients' diagnostic leukemic cells to cytarabine *in vitro*. The difficulty of obtaining bone marrow samples and the *in vitro* cytarabine chemosensitivity in primary AML cells is probably the reason for the lack of such studies, especially in pediatric patients.

RESULTS {#s2}
=======

Patient demographics {#s2_1}
--------------------

The current study included 65 patients enrolled in the multi-center St. Jude AML02 clinical trial with specimens available for determination of *in vitro* leukemic cell cytarabine chemosensitivity. Of these 65 patients, 50 (including 40 white patients) had leukemic cells with *in vitro* cytarabine with IC50 \< 5 ng/μL and 15 (including 10 white patients) had leukemic cells that were resistant to cytarabine (IC50 not achieved). The baseline demographics of the patients included in the study are summarized in Table [1](#T1){ref-type="table"}. There was no significant difference in age, gender and race between the patients classified as having leukemic cells sensitive or resistant to cytarabine. However, as expected, patients with high-risk group features were more abundant in cytarabine resistant cases. Given that our overall sample size was limited and most (77%) of the participants were genetically white and had a similar proportion of resistant vs. sensitive cases as the whole cohort, we restricted our analysis to the 50 genetically white patients.

###### Characteristics of patients included in the present study

  Characteristic               All patients^\*^ (n=65)   Caucasians (n=50)                                    
  ---------------------------- ------------------------- ------------------- ------- ------------ ----------- -------
  **Age in years (mean±SD)**   11.4 ± 5.2                8.8 ± 6.3           0.159   10.9 ± 4.0   8.6 ± 6.5   0.295
  **Female sex**               8 (53.3)                  26 (52)             0.928   5 (50)       21 (52.5)   0.887
  **Race**                                                                   0.282                            \-
   **Caucasian**               10 (66.7)                 40 (80)                     \-           \-          
   **Black**                   5 (33.3)                  10 (20)                     \-           \-          
  **Initial risk group**                                                     0.002                            0.002
   **Low**                     2 (13.3)                  17 (34)                     0 (0)        14 (35)     
   **Standard**                3 (20)                    24 (48)                     3 (30)       20 (50)     
   **High**                    10 (66.7)                 9 (18)                      7 (70)       6 (15)      

Values are presented as number (percentage) unless otherwise noted.

^\*^ All patients comprise of 50 Caucasians and 15 Blacks.

Genome-wide association analysis {#s2_2}
--------------------------------

After rigorous quality control (QC) as described in the methods below, we evaluated 1,317,106 variants in 50 white patients. With this limited sample size, none of the SNPs reached genome-wide significance at the Bonferroni threshold for the familywise error rate (P\<5 × 10^-8^; Figure [1](#F1){ref-type="fig"}). Nevertheless, as our study likely has the largest feasible sample size in this rare disease setting, we selected 113 SNPs with p \< 0.0001 to evaluate for further scientific evidence of involvement in cytarabine response (Table [2](#T2){ref-type="table"}).

![The Manhattan plot showing results of the genome-wide SNP association analysis with *in vitro* cytarabine IC50 of diagnostic leukemic cells within white pediatric AML patients\
The y-axis is -- log10 the association p-value for the SNPs and the x-axis shows the chromosomal locations of the SNPs. The red line is the genome-wide significance threshold (P=5x10^-8^) and the blue line is the suggestive threshold (P=1x10^-4^).](oncotarget-09-34859-g001){#F1}

###### List of 113 SNPs with suggestive level of association (P\<1.0x10^-4^) with *in vitro* cytarabine chemo-sensitivity of diagnostic leukemic cells from AML patients enrolled on multicenter St. Jude AML02 clinical trial

  SNP           Chr   Location relative to nearest gene               Gene Name                                                            P-value   Direction of association with minor allele
  ------------- ----- ----------------------------------------------- -------------------------------------------------------------------- --------- --------------------------------------------
  rs17030128    1     37kb 5\' of CTTNBP2NL                           CTTNBP2 N-terminal like                                              0.00004   Resistance
  rs78755594    1     509kb 5\' of LOC642587                          MIR205 host gene                                                     0.00004   Resistance
  rs12730413    1     Within TNFSF4                                   Tumor necrosis factor superfamily, member 4                          0.00002   Resistance
  rs11123318    2     Within DPP10                                    Dipeptidyl peptidase like 10                                         0.00009   Resistance
  rs2384234     2     Within DTNB                                     Dystrobrevin beta                                                    0.00001   Resistance
  rs12472283    2     Within DTNB                                     Dystrobrevin beta                                                    0.00003   Resistance
  rs13025966    2     Within DTNB                                     Dystrobrevin beta                                                    0.00003   Resistance
  rs17745923    2     Within DTNB                                     Dystrobrevin beta                                                    0.00003   Resistance
  rs34104763    2     Within DTNB                                     Dystrobrevin beta                                                    0.00005   Resistance
  rs34736805    2     Within DTNB                                     Dystrobrevin beta                                                    0.00005   Resistance
  rs35921400    2     Within DTNB                                     Dystrobrevin beta                                                    0.00008   Resistance
  rs1869686     2     16kb 5\' of HNMT                                Histamine N-methyltransferase                                        0.00008   Resistance
  rs2241028     2     Within HTRA2                                    HtrA serine peptidase 2                                              0.00004   Resistance
  rs1437352     2     Within LRP1B                                    Low density lipoprotein receptor related protein 1B                  0.00005   Sensitivity
  rs16847711    2     Within LRP1B                                    Low density lipoprotein receptor related protein 1B                  0.00009   Resistance
  rs7565278     2     5\' of TGFA and 26kb 3\' of ADD2                Transforming growth factor alpha and adducin 2                       0.00004   Resistance
  rs12714411    2     60kb 3\' of TMEM18                              Transmembrane protein 18                                             0.00008   Resistance
  rs16850901    3     215kb 5\' of ALCAM                              Activated leukocyte cell adhesion molecule                           0.00004   Resistance
  rs11719029    3     17kb 5\' of CX3CR1                              C-X3-C motif chemokine receptor 1                                    0.00002   Resistance
  rs11927011    3     723kb 5\' of MIR4790                            MicroRNA 4790                                                        0.00008   Resistance
  rs6773395     3     725kb 5\' of MIR4790                            MicroRNA 4790                                                        0.00008   Resistance
  rs9835716     3     735kb 5\' of MIR4790                            MicroRNA 4790                                                        0.00010   Resistance
  rs11934226    4     970kb 3\' of C4orf33                            Chromosome 4 open reading frame 33                                   0.00000   Resistance
  rs7664923     4     958kb 3\' of C4orf33                            Chromosome 4 open reading frame 33                                   0.00000   Resistance
  rs111261849   4     973kb 3\' of C4orf33                            Chromosome 4 open reading frame 33                                   0.00001   Resistance
  rs62309493    4     460kb 3\' of C4orf33                            Chromosome 4 open reading frame 33                                   0.00004   Resistance
  rs4253418     4     Within F11                                      Coagulation factor XI                                                0.00004   Resistance
  rs79827604    4     9.6kb 3\' of PRSS48                             Protease, serine 48                                                  0.00002   Resistance
  rs614158      4     4.1kb 5\' of SLIT2                              Slit guidance ligand 2                                               0.00006   Resistance
  rs640501      4     5.4kb 5\' of SLIT2                              Slit guidance ligand 2                                               0.00006   Resistance
  rs9991282     4     Within UNC5C                                    Unc-5 netrin receptor C                                              0.00004   Resistance
  rs73838827    4     Within UNC5C                                    Unc-5 netrin receptor C                                              0.00009   Resistance
  rs2062416     4     60kb 3\' of VEGFC                               Vascular endothelial growth factor C                                 0.00005   Resistance
  rs62370525    5     232kb 3\' of FBXO4                              F-box protein 4                                                      0.00002   Resistance
  rs34115593    5     Within FGF1                                     Fibroblast growth factor 1                                           0.00002   Resistance
  rs71587226    5     Within FGF1                                     Fibroblast growth factor 1                                           0.00003   Resistance
  rs6884797     5     Within FGF1                                     Fibroblast growth factor 1                                           0.00004   Resistance
  rs17574650    5     Within GHR                                      Growth hormone receptor                                              0.00002   Resistance
  rs9324859     5     3.1kb 5\' of LOC729080                          Glycine cleavage system protein H (aminomethyl carrier) pseudogene   0.00007   Resistance
  rs17797667    5     25kb 3\' of NPY6R                               neuropeptide Y receptor Y6 (pseudogene)                              0.00002   Resistance
  rs4645358     5     2.1kb 5\' of PCDH1                              protocadherin 1                                                      0.00007   Resistance
  rs72923772    6     277kb 5\' of MIR4643                            microRNA 4643                                                        0.00008   Resistance
  rs9368620     6     NEDD9                                           neural precursor cell expressed                                      0.00006   Resistance
  rs356973      6     ZNRD1-AS1                                       Zinc Ribbon Domain Containing 1 Antisense, Pseudogene                0.00004   Resistance
  rs17798136    7     39kb 3\' of BBS9                                Bardet-Biedl syndrome 9                                              0.00004   Resistance
  rs2174362     7     5.9kb 5\' of ZC3HAV1                            zinc finger CCCH-type containing, antiviral 1                        0.00000   Resistance
  rs76651618    7     10kb 5\' of ZC3HAV1                             zinc finger CCCH-type containing, antiviral 1                        0.00000   Resistance
  rs59520763    7     2.3kb 5\' of ZC3HAV1                            zinc finger CCCH-type containing, antiviral 1                        0.00008   Resistance
  rs270066      8     CSMD1                                           CUB and Sushi multiple domains 1                                     0.00001   Resistance
  rs4242513     8     CSMD1                                           CUB and Sushi multiple domains 1                                     0.00002   Resistance
  rs4493928     8     CSMD1                                           CUB and Sushi multiple domains 1                                     0.00002   Resistance
  rs55824821    8     CSMD1                                           CUB and Sushi multiple domains 1                                     0.00005   Resistance
  rs12542120    8     CSMD1                                           CUB and Sushi multiple domains 1                                     0.00008   Resistance
  rs897266      8     DLC1                                            DLC1 Rho GTPase activating protein                                   0.00008   Sensitivity
  rs7018361     8     DLC1                                            DLC1 Rho GTPase activating protein                                   0.00009   Sensitivity
  rs16939055    8     6.2kb 3\' of SNAI2                              snail family transcriptional repressor 2                             0.00006   Resistance
  rs13270346    8     TRPS1                                           transcriptional repressor GATA binding 1                             0.00008   Resistance
  rs199615944   9     1.8kb 5\' of C9orf144                           Family With Sequence Similarity 205 Member B, Pseudogene             0.00006   Resistance
  rs72717694    9     45kb 5\' of MIR873                              microRNA 873                                                         0.00004   Resistance
  rs16936272    9     506kb 3\' of TMEM38B                            transmembrane protein 38B                                            0.00005   Resistance
  rs6477500     9     502kb 3\' of TMEM38B                            transmembrane protein 38B                                            0.00005   Resistance
  rs77798124    9     500kb 3\' of TMEM38B                            transmembrane protein 38B                                            0.00005   Resistance
  rs7854098     9     502kb 3\' of TMEM38B                            transmembrane protein 38B                                            0.00005   Resistance
  rs10966448    9     909kb 3\' of TUSC1                              tumor suppressor candidate 1                                         0.00004   Resistance
  rs884889      10    1.6kb 3\' of ZMIZ1                              Zinc Finger MIZ-Type Containing 1                                    0.00007   Resistance
  rs12364729    11    30kb 5\' of LOC100507205                        uncharacterized LOC100507205                                         0.00005   Resistance
  rs77600532    11    OPCML                                           opioid binding protein/cell adhesion molecule like                   0.00002   Resistance
  rs545375      11    OPCML                                           opioid binding protein/cell adhesion molecule like                   0.00008   Resistance
  rs303825      12    1.7kb 3\' of FIGNL2                             fidgetin like 2                                                      0.00006   Resistance
  rs11067996    12    72kb 5\' of MED13L                              Mediator Complex Subunit 13 Like                                     0.00004   Resistance
  rs721947      12    93kb 3\' of NEDD1                               neural precursor cell expressed                                      0.00000   Resistance
  rs303815      12    SCN8A                                           sodium voltage-gated channel alpha subunit 8                         0.00004   Resistance
  rs303817      12    SCN8A                                           sodium voltage-gated channel alpha subunit 8                         0.00004   Resistance
  rs60637       12    SCN8A                                           sodium voltage-gated channel alpha subunit 8                         0.00004   Resistance
  rs747283      12    SCN8A                                           sodium voltage-gated channel alpha subunit 8                         0.00007   Resistance
  rs1905248     12    SCN8A                                           sodium voltage-gated channel alpha subunit 8                         0.00008   Resistance
  rs76411845    12    TBC1D30                                         TBC1 domain family member 30                                         0.00004   Resistance
  rs1112973     12    633kb 3\' of TRHDE                              thyrotropin releasing hormone degrading enzyme                       0.00005   Sensitivity
  rs7301109     12    635kb 3\' of TRHDE                              thyrotropin releasing hormone degrading enzyme                       0.00009   Sensitivity
  rs7996008     13    63kb 3\' of PCDH17                              protocadherin 17                                                     0.00009   Resistance
  rs72632692    13    1Mb 5\' of SLC10A2                              solute carrier family 10 member 2                                    0.00000   Resistance
  rs58540528    14    33kb 3\' of DLK1                                delta like non-canonical Notch ligand 1                              0.00007   Resistance
  rs75400242    15    147kb 3\' of FAM169B/360 kb upstream of IGF1R   Insulin like growth factor receptor 1                                0.00002   Resistance
  rs1974961     15    SHC4                                            SHC adaptor protein 4                                                0.00007   Resistance
  rs62011577    15    SLCO3A1                                         solute carrier organic anion transporter family member 3A1           0.00004   Resistance
  rs7182304     15    SLCO3A1                                         solute carrier organic anion transporter family member 3A2           0.00004   Resistance
  rs9889220     16    3.2kb 3\' of ADAD2                              adenosine deaminase domain containing 2                              0.00009   Resistance
  rs1376041     16    GPR56                                           G Protein-Coupled Receptor 56                                        0.00001   Resistance
  rs8051448     16    JPH3                                            junctophilin 3                                                       0.00002   Resistance
  rs9922685     16    SRL                                             sarcalumenin                                                         0.00002   Resistance
  rs7203855     16    72kb 5\' of ZNF423                              zinc finger protein 423                                              0.00004   Resistance
  rs9911336     17    SLC43A2                                         solute carrier family 43 member 2                                    0.00009   Resistance
  rs9967269     18    DLGAP1                                          DLG associated protein 1                                             0.00010   Sensitivity
  rs34381217    18    852kb 3\' of GALR1                              galanin receptor 1                                                   0.00004   Resistance
  rs4796870     18    169kb 3\' of VAPA                               VAMP associated protein A                                            0.00004   Resistance
  rs9957328     18    163kb 3\' of VAPA                               VAMP associated protein A                                            0.00008   Resistance
  rs2968180     19    BCAM                                            basal cell adhesion molecule                                         0.00001   Resistance
  rs7249750     19    BCAM                                            basal cell adhesion molecule                                         0.00004   Resistance
  rs4801739     19    BSPH1                                           binder of sperm protein log 1                                        0.00006   Resistance
  rs10408993    19    1.8kb 3\' of CBLC                               Cbl proto-oncogene C                                                 0.00004   Resistance
  rs78253907    19    CBLC                                            Cbl proto-oncogene C                                                 0.00004   Resistance
  rs4925251     20    CDH4                                            cadherin 4                                                           0.00004   Resistance
  rs6142655     20    CDH4                                            cadherin 4                                                           0.00004   Resistance
  rs6142792     20    CDH4                                            cadherin 4                                                           0.00004   Resistance
  rs62201785    20    CDH4                                            cadherin 4                                                           0.00004   Resistance
  rs67283024    20    CDH4                                            cadherin 4                                                           0.00004   Resistance
  rs4925252     20    CDH4                                            cadherin 4                                                           0.00005   Resistance
  rs34517760    21    47kb 5\' of SOD1                                superoxide dismutase 1, soluble                                      0.00004   Resistance
  rs56837868    22    495kb 3\' of MN1                                Meningioma 1 proto-oncogene (Transcriptional Regulator)              0.00004   Resistance
  rs2072712     22    NCF4                                            neutrophil cytosolic factor 4                                        0.00001   Resistance
  rs34072125    22    1.7kb 3\' of NCF4                               neutrophil cytosolic factor 4                                        0.00001   Resistance
  rs5995360     22    NCF4                                            neutrophil cytosolic factor 4                                        0.00001   Resistance
  rs6000462     22    287bp 3\' of NCF4                               neutrophil cytosolic factor 4                                        0.00001   Resistance

Abreviations: Chr: chromosome; SNP: Single nucleotide polymorphism.

The top GWAS SNP associated with cytarabine resistance is rs721947 (P=1.77x10^-7^). It is located on chromosome 12 downstream of *NEDD1* and co-localized within a long intergenic non-coding RNA (LincRNA) region. A few other potentially interesting SNPs localized within or close to the genes of potential relevance in myeloid malignancies. A synonymous SNP, rs1376041 G\>A (P=1.42x10^-5^), is located within a conserved region close to exon/intron splice junction within the G protein-coupled receptor 56 (*GPR56*) gene. Presence of the minor allele A for rs1376041 was associated with cytarabine resistance. Our results on this SNP are very exciting given that *GPR56* contributes to AML development and its expression has been associated with inferior outcome in AML.\[[@R18], [@R20]\] rs75400242 G\>A (P=2.1x10^-5^) SNP is located in a region upstream of *IGF1R* (Insulin like growth factor receptor) a gene expressed in human leukemia cell lines with pathological significance in AML \[[@R21]--[@R23]\]. *IGF1R* is among one of the significantly phosphorylated receptor tyrosine kinase in AML that has been associated with activation of PI3K/AKT signaling and thus cell growth and survival in AML \[[@R23]\].

rs56837868 G\>A (P=3.56x10^-5^) is located in a LincRNA ENSG00000233574 and is roughly 495 kb downstream of the transcriptional co-activator Meningioma1 (*MN1*) proto-oncogene. *MN1* overexpression has been reported to be an important step in the development of inv(16) AML, and is predictive of poor outcome in AML patients with normal cytogenetics.\[[@R24], [@R25]\] An intronic SNP, rs545375 A\>G (P=7.67x10^-5^), in opioid binding protein/cell adhesion molecule like (*OPCML*) occurs in high LD (r^2^=0.93, D'=1) with rs540923, which is an eQTL for Homeobox A10 (*HOXA10*), a well-known myeloid leukemia gene. rs7565278 is present around 26kb 3' of the adducin 2 beta (*ADD2*) gene and approximately 85kb 5' of the transforming growth factor alpha (*TGFA*) gene, which is expressed in neoplastic myeloblasts.

Several SNPs were located in or near cell adhesion genes (*ALCAM, BCAM, CDH4, NEDD9, OCML, PCDH1* and *PCDH17*) and genes involved death receptor signaling pathways (*HTRA2* and *ZC3HAV1a* PARP family member). SNPs with in or close to other biologically interesting genes included: *CXC3R1, a* chemokine receptor which is expressed at higher levels in AML \[[@R26]\]; *DLK1*, a member of the NOTCH signally pathway with a potentially oncogenic role in myeloid dysplastic syndrome \[[@R27]\], a disease that frequently progresses into AML; *VEGFC* (vascular endothelial growth factor C), for which higher expression has been previously associated with chemo-resistance and adverse prognosis in AML \[[@R28]\].

Expression quantitative trait loci (eQTL) analysis for differentially expressed genes {#s2_3}
-------------------------------------------------------------------------------------

We then evaluated the association of the expression of the genes using 578 unique microarray probe sets located within 500kb of the 113 SNPs identified in the GWAS analysis above. Thirty-eight probes representing 38 unique genes showed significant differential expression between the 10 cytarabine-resistant cases and the 40 cytarabine-sensitive cases (p \< 0.05; [Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Next, we determined cis-eQTL associations between expression levels of the 38 genes with differential expression between sensitive and resistant cell lines and the 113 identified SNPs. We identified 19 SNP-gene pairs among 13 unique SNPs and 12 unique genes with a concordant triad of associations (Table [3](#T3){ref-type="table"}): SNP genotype with cytarabine sensitivity (p \< 0.0001), mRNA expression with cytarabine sensitivity (p \< 0.05), and SNP genotype with mRNA expression (p \< 0.1). Five SNP-gene pairs were informatively redundant due to linkage among SNPs. Figures [2A-2C](#F2){ref-type="fig"} provides heat-maps illustrating the genotype distribution of the 13 SNPs between cytarabine sensitive and resistant leukemia cells as well expression levels of the 12 genes between cytarabine sensitive and resistant leukemia cells.

###### List of candidate SNP-gene pairs that passed all the three criteria -i) SNP associated with cytarabine *in vitro* sensitivity ii) gene within 500+/- of SNP was differentially expressed in resistant vs. sensitive cases and iii) SNP is associated with gene expression

  SNP           Probe ID       Gene Symbol   SNP-gene expression (*cis*-eQTL) P-value   Minor Allele association direction with gene-expression   Gene-expression vs. cytarabine *in vitro* sensitivity (P-value)   Gene-expression association direction in Resistant Cells   SNP vs. cytarabine *in vitro* Sensitivity P-value   Minor allele association direction with cytarabine *in vitro* sensitivity
  ------------- -------------- ------------- ------------------------------------------ --------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------- ---------------------------------------------------------------------------
  rs78253907    202264_s\_at   *TOMM40*      0.023                                      Low                                                       0.022                                                             Low                                                        0.0000356                                           Resistant
  rs2968180     202264_s\_at   *TOMM40*      0.010                                      Low                                                       0.022                                                             Low                                                        0.0000099                                           Resistant
  rs1974961     202766_s\_at   *FBN1*        0.046                                      High                                                      0.006                                                             High                                                       0.0000749                                           Resistant
  rs1376041     203163_at      *KATNB1*      0.049                                      High                                                      0.046                                                             High                                                       0.0000142                                           Resistant
  rs9889220     206043_s\_at   *ATP2C2*      0.040                                      High                                                      0.034                                                             High                                                       0.0000899                                           Resistant
  rs303825      208219_at      *ACVR1B*      0.019                                      High                                                      0.029                                                             High                                                       0.0000551                                           Resistant
  rs1905248     208219_at      *ACVR1B*      0.009                                      High                                                      0.029                                                             High                                                       0.0000767                                           Resistant
  rs17797667    210444_at      *NPY6R*       0.016                                      Low                                                       0.034                                                             Low                                                        0.000022                                            Resistant
  rs1376041     212070_at      *GPR56*       0.022                                      High                                                      0.036                                                             High                                                       0.0000142                                           Resistant
  rs11067996    212208_at      *MED13L*      0.033                                      High                                                      0.014                                                             High                                                       0.0000442                                           Resistant
  rs199615944   214484_s\_at   *SIGMAR1*     0.040                                      Low                                                       0.006                                                             Low                                                        0.0000558                                           Resistant
  rs9991282     214518_at      *PDHA2*       0.023                                      High                                                      0.003                                                             High                                                       0.0000374                                           Resistant
  rs75400242    rs208441_at    *IGF1R*       0.062                                      High                                                      0.031                                                             High                                                       0.0000219                                           Resistant
  rs4253418     221369_at      *MTNR1A*      0.031                                      High                                                      0.026                                                             High                                                       0.0000356                                           Resistant

rs78253907 within TOMM40 occurs in LD (r2=1) with rs10408993 and rs7249750rs303825 in ACVR1B occurs in LD (r2 =1) with rs303815, rs60637 and rs303817.

![SNP-genotype and gene-expression heat-map in cytarabine sensitive and resistant cases\
**(A)** Genotype heat-map for 13 unique SNPs between cytarabine sensitive and resistant cases. **(B)** Gene-expression heat-map of 12 genes showing expression differences between cytarabine sensitive and resistant cases. **(C)** Average gene-expression of 12 genes between cytarabine sensitive and resistant cases.](oncotarget-09-34859-g002){#F2}

Guided by the results above and existing evidence from literature on genes with relevance in AML, we further selected *GPR56* and *IGF1R* for further *in vitro* validation of the impact on cytarabine resistance in AML cell lines.

rs1376041-*GPR56* {#s2_4}
-----------------

*GPR56* has been reported previously to play a role in leukemogenesis \[[@R20]\]and has been recently identified to be part of a 17-gene leukemia stem cell signature, LSC17.\[[@R29]\] The *GPR56* SNP rs1376041 G\>A minor allele A was associated with cytarabine resistance (P=1.42x10^-5^, Figure [3A](#F3){ref-type="fig"}); greater *GPR56* mRNA expression levels in AML patients' diagnostic leukemic cells were associated with resistance to cytarabine (P=0.036, Figure [3B](#F3){ref-type="fig"}) and consistent with these, presence of rs1376041 minor allele A was associated with greater *GPR56* mRNA expression in leukemic cells (P=0.022, Figure [3C](#F3){ref-type="fig"}). Other genes in the flanking region within 500kb of the *GPR56* SNP include other G protein-coupled receptors, namely *GPR97* and *GPR114* (Figure [3D](#F3){ref-type="fig"}). In addition to the *cise*QTL association of rs1376041 with *GPR56* expression, a significant association was also observed with the neighboring gene *KATNB1* (Table [3](#T3){ref-type="table"}). We further investigated the impact of siRNA mediated transient knockdown of *GPR56* on cellular sensitivity to cytarabine. siRNA mediated knockdown resulted in a significant reduction in *GPR56* mRNA in both THP1 and K562 cell lines (P\<0.0005, Figure [4A](#F4){ref-type="fig"}). GPR56 knockdown resulted in significant increase in apoptosis as shown by increase in Annexin V assay (P\<0.01, Figure [4B](#F4){ref-type="fig"} and [4C](#F4){ref-type="fig"}) and reduction in cell viability (P\<0.05, Figure [4D](#F4){ref-type="fig"} and [4E](#F4){ref-type="fig"}) in response to cytarabine at 5μM and 200μM of cytarabine in both the cell lines.

![*GPR56* and rs1376041\
**(A)** Bar-plot showing the distribution of cytarabine sensitive and resistant cases within genotype groups for rs1376041. **(B)** Boxplot showing the association of leukemic cell *GPR56* gene expression levels between cytarabine sensitive and resistant cases. **(C)** Boxplot demonstrating association of rs1376041 genotypes with *GPR56* gene expression. In boxplots, the y-axis represents natural logarithm of gene expression and the x-axis shows the sensitive/resistant groups or genotype groups. The horizontal line inside the box represents the median value of each group, the lower hinge of the box represents the 25th percentile, the upper hinge represents the 75th percentile and the lower and upper whiskers here display 1.5 times the interquartile range. The outliers are defined as data points that fall outside of the first and third quartiles by more than 1.5 times the interquartile range. **(D)** Regional plot showing -log10 p-value of the association of SNPs with cytarabine *in vitro* sensitivity on the y-axis and genes on chromosome 16 within +/- 500kb from rs1376041 on the x-axis. As denoted by the legend with colors indicating linkage disequilibrium, rs1376041 was not in linkage disequilibrium with other SNPs within the region.](oncotarget-09-34859-g003){#F3}

![Impact of siRNA mediated knockdown of *GPR56* on cytarabine sensitivity in THP1 and K562 cell lines\
**(A)** *GPR56* mRNA levels in THP1 and K562 cells transfected with scrambled or GPR56 specific siRNAs. Impact of siRNA mediated knockdown of *GPR56* on apoptosis **(B** and **C)** and cell viability **(D** and **E)** post cytarabine treatment in THP1 and K562 cell lines. ^\*^P\<0.05, ^\*\*^P\<0.01, ^\*\*\*^P\<0.001, ^\*\*\*\*^P\<0.0001.](oncotarget-09-34859-g004){#F4}

rs75400242-*IGF1R* {#s2_5}
------------------

The second SNP-gene pair of interest is rs74500242- *IGF1R*, an insulin-like growth factor 1 receptor with tyrosine kinase activity. As shown in Figure [5A](#F5){ref-type="fig"}, the presence of the minor allele A for rs75400242 was associated with cytarabine resistance (P=2.19x10^-5^). Furthermore, *IGF1R* mRNA expression level within diagnostic leukemic cells was significantly higher in cytarabine resistant cases (P=0.031, Figure [5B](#F5){ref-type="fig"}). The presence of an A allele for rs75400242 showed a marginally significant association with greater *IGF1R* expression (P=0.062, Figure [5C](#F5){ref-type="fig"}). Other genes near rs75400242 include *ARRDC4* and *FAM169B* (Figure [5D](#F5){ref-type="fig"}).

![*IGF1R* and rs75400242\
**(A)** Bar-plot showing distribution of cytarabine sensitive and resistant cases within genotype groups for rs75400242. **(B)** Boxplot showing association of *IGF1R* gene expression with cytarabine sensitive and resistant cases. **(C)** Boxplot demonstrating association of rs75400242 with *IGF1R* gene expression. In boxplots, the y-axis represents natural logarithm of gene expression and the x-axis shows the sensitive/resistant groups or genotype groups. The horizontal line inside the box represents the median value of each group, the lower hinge of the box represents the 25th percentile, the upper hinge represents the 75th percentile and the lower and upper whiskers here display 1.5 times the interquartile range. The outliers are defined as data points that fall outside of the first and third quartiles by more than 1.5 times the interquartile range. **(D)** showing -log10 p-value of the association of SNPs with cytarabine *in vitro* sensitivity on the y-axis and genes on chromosome 15 within +/- 500kb from this rs75400242 on the x-axis. As denoted by the legend with colors indicating linkage disequilibrium, rs75400242 was not in linkage disequilibrium with other SNPs within the region.](oncotarget-09-34859-g005){#F5}

We further investigated the impact of siRNA mediated transient knockdown of *IGF1R* on cellular sensitivity to cytarabine. siRNA mediated knockdown resulted in reduction in *IGF1R* mRNA in THP1 and K562 cell lines (P\<0.05, Figure [6A](#F6){ref-type="fig"}). *IGF1R* knockdown enhanced apoptosis and correspondingly had reduced cell viability in response to cytarabine treatment, in THP1 cell lines (Figure [6B](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}) and K562 cell lines (Figure [6C](#F6){ref-type="fig"} and [6E](#F6){ref-type="fig"}).

![Impact of siRNA mediated knockdown of IGF1R on cytarabine sensitivity in THP1 and K562 cell lines\
**(A)** *IGF1R* mRNA levels in THP1 and K562 cells transfected with scrambled or *IGF1R* specific siRNAs. Impact of siRNA mediated knockdown of *IGF1R* on apoptosis **(B** and **C)** and cell viability **(D** and **E)** post cytarabine treatment in THP1 and K562 cell lines. ^\*^P\<0.05, ^\*\*^P\<0.01, ^\*\*\*^P\<0.001, ^\*\*\*\*P\<0.0001.^](oncotarget-09-34859-g006){#F6}

DISCUSSION {#s3}
==========

Development of resistance to cytarabine adversely impacts treatment outcome, making it very critical to understand the molecular mechanisms underlying cytarabine resistance. Past efforts to understand factors influencing cytarabine chemosensitivity have focused on the use of lymphoblast cell lines (LCLs) derived from healthy population as a model system or comparing gene-expression differences between parental and cytarabine resistant AML cells lines.\[[@R9]--[@R12]\] However, each of these systems have limitations as LCLs do not represent leukemic cells and AML cell lines can undergo changes in culture that might impact gene expression. In this study, we report the first GWAS analysis to identify genomic markers predictive of AML patients' leukemic cell cellular sensitivity to cytarabine. We identified 113 SNPs associated with cytarabine *in vitro* sensitivity of leukemic cells obtained from pediatric AML patients. Within 500 kb of these SNPs, there were 38 genes that were differentially expressed between cytarabine sensitive and resistant cases. Nineteen SNP-gene pairs fulfilled the following three criteria: (1) association of SNPs with cytarabine *in vitro* sensitivity (p\< 0.0001), (2) association of gene expression with cytarabine *in vitro* sensitivity (p\<0.05) and (3) association of SNP with gene expression in a consistent direction (p \< 0.1). Although this approach highlights significance of some SNPs, it is possible that other significant SNPs impact gene function by mechanisms other than regulating gene expression. Figure [7](#F7){ref-type="fig"} summarizes the overall results of the current study. Although in-depth mechanistic investigation of all the 113 SNPs is beyond the scope of this work study, we selected two genes GPR56 and IGF1R for further *in vitro* validation. Consistent with the SNP and gene-expression results, siRNA mediated knockdown of these genes increased cellular susceptibility to cytarabine. *GPR56,* also commonly referred to as *ADGRG1*, encodes for G protein-coupled adhesion molecule and is highly expressed in leukemic stem cells and has been implicated in development of AML.\[[@R30]\] We have previously shown higher expression of GPR56 to be predictive of inferior outcome and more recently our data shows a significant relationship between GPR56 methylation and expression with outcome in pediatric AML.\[[@R18]\], Consistent with our findings, another study investigating DNMT3B as a player in leukemogenesis reported GPR56 as one of the target genes of DNMT3B and in adult AML high expression of GPR56 was associated with inferior overall survival. \[[@R31]\] GPR56 is also part of the 17 gene leukemic stem cell score (LSC17) that has been recently shown to have prognostic significance in predicting therapy resistance and relapse risk.\[[@R32]\] Saito *et al.* showed greater *GPR56* expression in AML samples with high ecotopic viral integration site-1 expression (EVI1^high^), which is considered a refractory type with poor prognosis. Further, *GPR56* knockdown in mice has been shown to result in an increase in cell migration and a decrease in cellular adhesion to the extracellular matrix, resulting in a reduction in cell growth rate and enhanced apoptosis.\[[@R20]\].

![Overall summary of results from the current analysis](oncotarget-09-34859-g007){#F7}

Our results show that the A allele of the *GPR56* rs1376041 SNP was associated with cytarabine resistance as well as with higher mRNA expression levels of *GPR56* gene, which in turn was associated with greater cytarabine resistance. This result indicates that rs1376041 SNP's contribution to cytarabine *in vitro* sensitivity might actually be through its regulation of *GPR56* gene expression levels. This adds a unique level of evidence indicating *GPR56* rs1376041 SNP to be predictive of its expression and cytarabine chemosensitivity of patient leukemia cells. Further, *GPR56* knockdown in AML cell lines increased cytarabine sensitivity, suggesting its potential role in drug resistance and thus inferior outcome. To the best of our knowledge, even though recent data suggests significant role of GPR56 in AML, SNPs in GPR56 have not been studied in context of developing AML or resistance to treatment response.

The second signal, the rs75400242 SNP, is a G\>A intronic SNP located 360 kb upstream of *IGF1R*, a gene encoding a transmembrane receptor protein having tyrosine kinase activity.\[[@R33], [@R34]\] Upon activation by insulin-like growth factor 1 (IGF-1), the IGF system regulates proliferation and differentiation of hematopoietic cells.\[[@R35]\] Activated *IGF1R*, can lead to upregulation of phosphoinositide 3 kinase/protein kinase B (PI3K/Akt) signaling, promoting growth and survival of AML cells.\[[@R23], [@R36]\] Cell growth and survival through *IGF1R* receptor-mediated activation of the PI3K/Akt signaling pathway has been reported previously \[[@R23], [@R37], [@R38]\], however its association with development of drug resistance is limited. Our results show *IGF1R* to be associated with cytarabine *in vitro* chemosensitivity and in conjunction with reports of specific targeting of IGF1/IGF1R signaling pathway having potent anti-leukemic activity in AML cells with constitutive PI3K activation, makes it a likely drug target.

Our study clearly adds another level of evidence by mapping a genetic variation that is predictive of leukemic cell cytarabine resistance. Although further studies are warranted to both validate the associations of SNPs identified in our study and to understand the functional underpinnings of the mechanisms contributing to cytarabine resistance, this is difficult due to the lack of such data sets owing to the practical challenges associated with obtaining *in vitro* drug sensitivity data from primary leukemia cells. To the best of our knowledge, even though limited by the relatively small sample size as compared to other GWAS studies, our study is the largest data set with *in vitro* cytarabine chemosensitivity in leukemic cells from pediatric AML patients.

In conclusion, although future work in larger clinical cohorts is warranted, our results identified SNPs, mapping to genes of relevance in AML.

MATERIALS AND METHODS {#s4}
=====================

Patient cohort {#s4_1}
--------------

This study included patients that were treated under the multicenter AML02 clinical trial ([ClinicalTrials.gov](https://clinicaltrials.gov/) identifier: NCT00136084). AML02 patients with t\[[@R8];[@R21]\], inv \[[@R16]\], or t\[[@R9];[@R11]\] chromosome abnormalities were classified as having low-risk AML. High-risk AML classification included those with -7, *FLT3*-ITD mutation, t\[[@R6];[@R9]\], megakaryoblastic AML, treatment-related AML, or AML arising from MDS. Patients lacking low or high-risk group features were classified as standard-risk AML. Details of study population and outcome data has been previously reported.\[[@R2]\] Primary bone marrow samples at diagnosis from 65 patients were available to perform *in vitro* cytotoxicity study. The mononuclear cells were isolated using Ficoll-Hypaque density-gradient centrifugation within 24 h. Cells were resuspended in modified RPMI-1640 medium supplemented with 20% fetal calf serum, penicillin (100 IU/mL), streptomycin (100 μg/mL) and Fungizone™ (Invitrogen; 0.125 μg/mL), as well as ITS medium supplement containing insulin (5 ng/mL), transferrin (5 μg/mL), and sodium selenite (5 ng/mL), as previously described.\[[@R39]\] In the event the blast count was \<80%, samples were enriched to achieve more than 80% blasts using magnetic cell sorting (Miltenyi Biotech, Germany). The sensitivity of leukemic cells to cytarabine was determined *in vitro* using the 4-day 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay.\[[@R18]\] The leukemic cells were exposed to six different concentrations of cytarabine (ranging from 0.002--2.5 ng/μL) or to culture media (without drug) in a 96-well plate. MTT assay was performed after 96 hrs of drug treatment to determine cytarabine IC50. Fifteen patient samples did not achieve IC50 even at highest drug concentration tested, which was 2.5 ng/μL. Therefore, IC50 values from the 65 samples were dichotomized into those less than 5 ng/μL, which represented the sensitive group (n=50 total, n=40 Caucasians), and those that did not achieve IC50, represented as a resistant group (n=15 total, n=10 Caucasians).

Genotyping {#s4_2}
----------

The genomic DNA samples of the AML02 participants were genotyped using the Illumina Omni 2.5M and Exome Beadchip (Illumina, San Diego, CA, USA) at Hussman Institute for Human Genomics, University of Miami, Miami FL, USA. Genotype calling was performed using Illumina\'s Genome Studio software V2011.1 (Illumina, San Diego, CA, USA).

Gene expression {#s4_3}
---------------

The mRNA expression levels in diagnostic leukemic blasts from the patient samples were previously determined using the Affymetrix U133A microarray data.\[[@R40]\] All gene expression values were natural log transformed prior to data analysis.

Quality control procedure {#s4_4}
-------------------------

QC steps were performed to obtain a high quality dataset for use in statistical analysis. QC is crucial since the capability of a GWAS to reveal true associations and the utility of those GWAS results is dependent on the quality of the data with significant impact on downstream analyses and replication studies.\[[@R41]\]The initial dataset had 2,612,357 variants and 65 participants. Marker QC comprised of filtering out 21,442 low quality SNPs having call rate ≤95% and 578,851 monomorphic SNPs. Of the remaining SNPs, the non-mitochondrial/non-haploid SNPs with MAF\>5% were the ones analyzed. Multi-step sample QC procedure included identification and removal of individuals with a large proportion of SNPs failing i.e samples with a call rate ≤95%, individuals with mismatch between genetic and reported sex, related or duplicated individuals and individuals with outlying heterozygosity rate.\[[@R41], [@R42]\] Sample QC also confirmed the individual's identified race and if genetic race was not consistent with their reported race, it was reassigned. All the samples passed sample QC steps and none were excluded in the analysis. Details of the QC procedure can be found in the [Supplementary Table 2](#SD1){ref-type="supplementary-material"}. All QC steps were performed using PLINK 1.9.\[[@R43], [@R44]\].

Statistical analysis {#s4_5}
--------------------

Given the phenotype of interest, namely cytarabine IC50, was not normally distributed ([Supplementarty Figure 1](#SD1){ref-type="supplementary-material"}), the patients were classified into two groups: cytarabine sensitive: leukemic cells with IC50 less than 5 ng/μL, (n= 40 Caucasian patients), and cytarabine resistant: leukemic cells that never achieved IC50 and thus were assigned IC50 of 5 ng/μL, (n= 10 Caucasian patients). We utilized Cochran-Armitage trend test to assess SNPs associated with cytarabine sensitive or resistant groups within our white patients.\[[@R43], [@R44]\] Genome-wide significance was set at an alpha level of 5x10^-8^ \[[@R45]\] and a suggestive level was set at 1x10^-4^ for follow-up with gene expression data. All GWAS was conducted using PLINK 1.9.\[[@R43], [@R44]\].

Gene-expression analysis {#s4_6}
------------------------

Differential gene expression for genes within +/-500kb of the significant/suggestive GWAS SNPs was conducted using Wilcoxon test to detect genes differentially expressed between the sensitive and resistant groups. *cis* eQTL analysis was conducted on candidate SNP-gene pairs identified in the GWAS and differential gene expression analysis above using Wilcoxon and Kruskal-Wallis tests, depending on how many genotype groups are available for each SNP. These analyses were done using R statistical software version 3.4.0.\[[@R46]\].

*In vitro* functional validation {#s4_7}
--------------------------------

*In vitro* validation of two genes identified in GWAS and validated in gene expression analysis was performed using AML cell lines: THP-1, K562 (ATCC, Manassas, VA, USA). The cell lines were maintained in RPMI-1640 (Invitrogen, USA) supplemented with 10% FBS (Invitrogen, USA) at 37°C in a humidified atmosphere containing 5% CO2. The cells were passaged every 2--3 days in order to maintain them in logarithmic growth phase. siRNAs targeting *GPR56* and *IGF1R* as well as scrambled siRNA were procured from Dharmacon (Accell SMARTpool, USA). Just before transfection, the cells were grown in RPMI-1640-medium free of antibiotics. Delivery of siRNA at a final concentration of 50 nM was performed using RNAi Max reagent (Invitrogen, USA) according to the manufacturer\'s instructions. To monitor the effect of siRNA on gene silencing, transfection (5 × 105 cells/well) was done in 6-well plates for 48 hours. RNA levels of target genes *GPR56* and *IGF1R* as well as house-keeping gene *GAPDH* was then measured by Taqman gene expression assays (ThermoFisher Scientific, USA). Transfected cells harvested and exposed to cytarabine at 5 μM and 200 μM final concentration for 48 hours. Cells were stained with acridine orange (AO) and propidium iodide (PI) for viability assays and fluorescein isothiocyanate-conjugated Annexin V for apoptosis assays followed by manufacturer's procedure, (Cellometer Inc., Lawrence, MA, USA). Cell imaging was undertaken by the Cellometer Vision CBA and FCS Express-6 software. In order to measure threshold in the software, it was set to 0% to quantify total fluorescence of each counted cell from the captured images. Based on fluorescence intensities, the results were calculated and converted to FCS file for analysis in the De Novo Software.55.
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AML

:   Acute Myeloid Leukemia

Ara-C

:   1-β-Arabinofuranosylcytosine or cytarabine

CML

:   Chronic Mylogenous Leukemia

eQTL

:   Expression Quantitative Trait Loci

EVI1

:   Ecotropic Viral Integration Site-1

GPR56

:   G Protein-Coupled Receptor 56

GWAS

:   Genome-Wide Association Analysis Study

HOXA10

:   Homeobox A10

HWE

:   Hardy-Weinberg Equilibrium

IBS/IBD

:   Identity-By-State/Identity-By-Descent

IC50

:   Half Maximal (50%) Inhibitory Concentration

IGF1

:   Insulin-like Growth Factor 1

IGF1R

:   Insulin like Growth Factor 1 Receptor

LCLs

:   Lymphoblastoid Cell Lines

LD

:   Linkage Disequilibrium

LincRNA

:   Long Intergenic Non-Coding RNA

MAF

:   Minor Allele Frequency

MN1

:   Meningioma 1

MRD

:   Minimal Residual Disease

MTT

:   4-day 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

OPCML

:   Opioid Binding Protein/Cell Adhesion Molecule Like

OS

:   Overall Survival

PC

:   Principal Component

PCA

:   Principal Component Analysis

PI3K/Akt

:   Phosphoinositide 3 Kinase/Protein Kinase B

QC

:   Quality Control
